The Week In... Pharma (27/04-01/05)
  • Posted on: 01/05/2020
  • Category: Industry

The Week In... Pharma (27/04-01/05)

Astra Zeneca and MSD’s Lynparza shows a survival benefit in prostate cancer patients, world leaders back the WHO’s COVID-19 drive, diagnostics specialist Novacyt are to supply the DHSC with COVID-19 tests, and millions of Australians download a coronavirus tracing app.

Interested in Star’s innovative outsourcing and resourcing solutions?

Contact Operations Director, Mark Ward, on 07872 105 540 or email

On the hunt for a new role, or just curious?

Visit our candidate page, submit your CV to, or give our offices a ring!

AZ/MSD's Lynparza shows survival benefit in prostate cancer patients

AstraZeneca and MSD's Lynparza (olaparib) has demonstrated an overall survival benefit in a late-stage trial for BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer.

World leaders – minus US, China – back WHO’s COVID-19 drive

The show of unity behind the Access to COVID-19 Tools (ACT) Accelerator included French President Emmanuel Macron, German Chancellor Angela Merkel and European Commission President Ursula von der Leyen, along with leaders from Africa, the Middle East and Asia.

Coronavirus: How India will play a major role in a Covid-19 vaccine

India is among the largest manufacturer of generic drugs and vaccines in the world. It is home to half a dozen major vaccine makers and a host of smaller ones, making doses against polio, meningitis, pneumonia, rotavirus, BCG, measles, mumps and rubella, among other diseases.

Novacyt to supply DHSC with COVID-19 tests

Diagnostics specialist Novacyt has signed a supply contract with the UK Department of Health and Social Care (DHSC) for its COVID-19 (CE IVD) polymerase chain reaction (PCR) test, developed by Primerdesign, the company’s molecular diagnostics division based in the UK.

Millions of Australians download coronavirus contact tracing app

More than two million people in Australia have downloaded a coronavirus tracing app developed by the country’s government a day after its release.

While you’re here…

…and are interested in our content, why not sign up to our newsletter?

It’s just below here.